Spots Global Cancer Trial Database for lung adenocarcinoma
Every month we try and update this database with for lung adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma | NCT02951897 | Lung Adenocarci... Diagnoses Disea... Circulating Tum... Treatment | lobectomy segmentecomy chemotherapy（pe... Lymphadenectomy CanPatrolTM to ... | 45 Years - 70 Years | Third Military Medical University | |
| Blood Detection of EGFR Mutation For Iressa Treatment | NCT02282267 | Lung Adenocarci... | Gefitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | NCT05675033 | Lung Adenocarci... Stage IV Non-sm... PD-1 Inhibitor VEGF | Serplulimab and... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| TCM in the Treatment of Lung Adenocarcinoma | NCT04482829 | Lung Adenocarci... | Jing-yan-kang G... PC chemotherapy... | 18 Years - 75 Years | Henan University of Traditional Chinese Medicine | |
| Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | NCT06056115 | Lung Adenocarci... | Tislelizumab,Pl... | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | NCT02186847 | Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Non-Small Cell ... Recurrent Non-S... Squamous Cell L... Stage IIIA Non-... Stage IIIB Non-... | Radiation Thera... Carboplatin Metformin Paclitaxel | 18 Years - | NRG Oncology | |
| Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2 | NCT02132143 | Lung Adenocarci... | intensity-modul... intensity-modul... | 18 Years - 75 Years | People's Hospital of Guangxi | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | NCT01851096 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | NCT01294306 | Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Squamous Cell L... | Akt Inhibitor M... Erlotinib Hydro... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung | NCT05228795 | Lung Cancer Ade... Lung Cancer Squ... Mesothelioma; L... | - | Sohag University | ||
| Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma | NCT01249053 | Lung Adenocarci... | 25 Years - 85 Years | China Medical University Hospital | ||
| Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | NCT04554875 | Cryptococcosis Lung Adenocarci... | A scoring syste... | - | Shanghai Pulmonary Hospital, Shanghai, China | |
| NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | NCT01819428 | Adenocarcinoma ... Adenocarcinoma ... | NOV120101 (Pozi... | 20 Years - | National OncoVenture | |
| Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma | NCT06104709 | Lung Adenocarci... Local Cryoablat... | 18 Years - 90 Years | China-Japan Friendship Hospital | ||
| Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | NCT02980991 | Lung Adenocarci... | Pemetrexed Cisplatin | 18 Years - 75 Years | Fudan University | |
| Exhaled Breath Particles in Lung Cancer | NCT05395611 | Lung Cancer Non-small Cell ... Lung Adenocarci... Squamous Cell L... | EBPcollected us... | 16 Years - 90 Years | Lund University Hospital | |
| Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | NCT03704870 | Lung Cancer Lung Diseases Lung Cancer, No... Surgery Lung Adenocarci... | Chest Xray No daily chest ... | 18 Years - | University Health Network, Toronto | |
| Metformin in Stage IV Lung Adenocarcinoma | NCT01997775 | Non-small Cell ... | METFORMIN | 20 Years - 80 Years | National Cheng-Kung University Hospital | |
| Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04625647 | Lung Adenocarci... Lung Non-Small ... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Sotorasib | 18 Years - | SWOG Cancer Research Network | |
| Lung Nodule Prospective Database | NCT03922828 | Lung Neoplasms Lung Cancer Lung Adenocarci... | CT scans | 21 Years - 120 Years | Singapore General Hospital | |
| Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | NCT04929041 | Lung Adenocarci... Lung Adenosquam... Lung Non-Small ... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... Quality-of-Life... Stereotactic Bo... | 18 Years - | National Cancer Institute (NCI) | |
| Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | NCT02691871 | Lung Adenocarci... | Apatinib (250 m... Apatinib (500 m... Apatinib (750 m... | 18 Years - 65 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma | NCT01588704 | Lung Cancer | Neoadjuvant Bev... | 18 Years - 65 Years | Sun Yat-sen University | |
| Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | NCT06255197 | Lung Cancer Lung Adenocarci... Lung Squamous C... Non Small Cell ... Small-cell Lung... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | ||
| Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | NCT03905317 | Lung Adenocarci... | Bevacizumab Inj... chest radiation concurrent chem... | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma | NCT01588704 | Lung Cancer | Neoadjuvant Bev... | 18 Years - 65 Years | Sun Yat-sen University | |
| Milademetan in Advanced/Metastatic Solid Tumors | NCT05012397 | Solid Tumors Head and Neck C... Cholangiocarcin... Sarcoma Lung Adenocarci... Bladder Urothel... Stomach Adenoca... Breast Cancer I... Ovarian Carcino... Cervical Cancer Non Small Cell ... Gastric Cancer Biliary Tract C... Melanoma Pancreas Cancer MDM2 Gene Ampli... Testicular Germ... Adrenocortical ... | RAIN-32 | 18 Years - | Rain Oncology Inc | |
| Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | NCT03904563 | Lung Adenocarci... | Bevacizumab chest radiation concurrent chem... | 18 Years - 75 Years | Sun Yat-sen University | |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT00955305 | Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Stage IV Non-Sm... Bronchioloalveo... | Bevacizumab Carboplatin Cixutumumab Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma | NCT05925764 | Lung Adenocarci... Whole Slide Ima... Novel Grading S... | Whole Slide Ima... | 20 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | NCT02787447 | Lung Adenocarci... | TKI Thoracic Hypofr... Thymosin Alpha ... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| Molecular Analysis of 150 Lung Adenocarcinoma | NCT02843711 | Lung Adenocarci... | Sequencing | 18 Years - 99 Years | Hospices Civils de Lyon | |
| Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | NCT00716456 | Lung Adenocarci... | erlotinib with ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | NCT00126581 | Lung Adenocarci... Lung Adenosquam... Malignant Peric... Malignant Pleur... Minimally Invas... Stage IIIB Lung... Stage IV Lung N... | Carboplatin Erlotinib Erlotinib Hydro... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2 | NCT02132143 | Lung Adenocarci... | intensity-modul... intensity-modul... | 18 Years - 75 Years | People's Hospital of Guangxi | |
| A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | NCT03076164 | Lung Adenocarci... Lung Cancer Lung Cancer Met... Lung Cancer Sta... Recurrent Lung ... Recurrent Lung ... | Trametinib Erlotinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | NCT04119024 | Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S... | Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi... | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | NCT02450903 | Non-Small-Cell ... | LDK378 | 18 Years - | Novartis | |
| Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma | NCT01249066 | Lung Adenocarci... | 25 Years - 85 Years | China Medical University Hospital | ||
| Identify Prognostic Biomarkers of Lung Cancer | NCT05010330 | Lung Cancer Lung Adenocarci... Lung Squamous C... Non Small Cell ... | 18 Years - 80 Years | RenJi Hospital | ||
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | NCT05198830 | Lung Adenocarci... Lung Large Cell... Lung Non-Squamo... Stage III Lung ... | Carboplatin Cisplatin Computed Tomogr... Durvalumab Magnetic Resona... Methoxyamine Pemetrexed Positron Emissi... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | NCT03704870 | Lung Cancer Lung Diseases Lung Cancer, No... Surgery Lung Adenocarci... | Chest Xray No daily chest ... | 18 Years - | University Health Network, Toronto | |
| NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | NCT01819428 | Adenocarcinoma ... Adenocarcinoma ... | NOV120101 (Pozi... | 20 Years - | National OncoVenture | |
| Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | NCT04965831 | Lung Adenocarci... | Furmonertinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | NCT01578551 | Carcinoma, Non-... Lung Adenocarci... | Paclitaxel Carboplatin Bevacizumab Metformin | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers | NCT01502202 | Non Small Cell ... Adenocarcinoma | Gefitinib Placebo Pemetrexed plus... | 18 Years - | National Cancer Center, Korea | |
| Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma | NCT05925764 | Lung Adenocarci... Whole Slide Ima... Novel Grading S... | Whole Slide Ima... | 20 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Tumor Microenvironment | NCT05982574 | Lung Adenocarci... | 18 Years - 90 Years | University Hospital Heidelberg | ||
| Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma | NCT04339218 | Lung Adenocarci... Cryotherapy Eff... | Cryoablation Pembrolizumab Pemetrexed Carboplatin | 18 Years - | Institut Bergonié | |
| Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis | NCT04692935 | Adenocarcinoma ... | 18 Years - 85 Years | Peking University People's Hospital | ||
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | NCT02788058 | Lung Adenocarci... EGFR Positive N... | EGFR-TKI Thoracic Hypofr... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | NCT05717803 | Segmentectomy Lung Adenocarci... | Segmentectomy | 18 Years - 80 Years | Fudan University | |
| Shared Decision Making in Patients With Lung Cancer | NCT05191485 | Surgery Lung Adenocarci... | Qualitative int... | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | NCT04937283 | Lung Adenocarci... | Segmentectomy w... Lobectomy with ... | 20 Years - 79 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants | NCT04370860 | EGFR Exon 19 Mu... Tumor Progressi... | 20 Years - 90 Years | National Taiwan University Hospital | ||
| Radiomics Multifactorial Biomarker for Pulmonary Nodules | NCT03872362 | Lung Neoplasms Carcinoma, Non-... Lung Diseases Neoplasms Pathology | radiomics | 18 Years - | Maastricht University | |
| A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test | NCT02738684 | Lung Adenocarci... | 18 Years - | Southwest Hospital, China | ||
| An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | NCT05558904 | Lung Adenocarci... | Alpha-methyl-4-... Computed Tomogr... Laboratory Biom... Positron Emissi... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer | NCT03199651 | Cigarette Smoke... Current Smoker Lung Adenocarci... Squamous Cell L... Stage IV Non-Sm... | Best Practice Biospecimen Col... Biospecimen Col... Laboratory Biom... Medical Chart R... Quality-of-Life... Questionnaire A... Smoking Cessati... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT00334815 | Lung Adenocarci... Lung Adenosquam... Lung Large Cell... Lung Squamous C... Minimally Invas... Stage IIIA Lung... Stage IIIB Lung... | Bevacizumab Cisplatin Docetaxel Etoposide Filgrastim Pegfilgrastim Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT01386385 | Lung Adenocarci... Lung Adenocarci... Lung Large Cell... Lung Squamous C... Minimally Invas... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... | 3-Dimensional C... Carboplatin Laboratory Biom... Paclitaxel Placebo Adminis... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Single-arm Exploratory Study of Neoadjuvant Therapy | NCT05527808 | Lung Adenocarci... | Tislelizumab pemetrexed cis-platemum or carboplatin | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | NCT00950365 | Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Stage IIIB Non-... Stage IV Non-Sm... | Erlotinib Hydro... Laboratory Biom... Pemetrexed Diso... | 18 Years - | Albert Einstein College of Medicine | |
| Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | NCT05558904 | Lung Adenocarci... | Alpha-methyl-4-... Computed Tomogr... Laboratory Biom... Positron Emissi... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | NCT05537922 | Non Small Cell ... Lung Cancer Met... Lung Cancer, No... Lung Adenocarci... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
| Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | NCT06031181 | Lung Adenocarci... Frozen Section Sublobar Resect... | Sublobar Resect... | 18 Years - 80 Years | Fudan University | |
| Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma | NCT05925764 | Lung Adenocarci... Whole Slide Ima... Novel Grading S... | Whole Slide Ima... | 20 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection | NCT05517811 | Liver Cancer Esophageal Canc... Colorectal Canc... Lung Adenocarci... Control Pancreas Cancer Biliary Cancer | TEG indices | 18 Years - 99 Years | University of Colorado, Denver | |
| Whole-Exome Sequencing (WES) of Cancer Patients | NCT02127359 | Lung Adenocarci... Colon Adenocarc... | 18 Years - | Dana-Farber Cancer Institute | ||
| Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | NCT02951637 | Lung Adenocarci... | Pemetrexed plus... Gefitinib | 18 Years - 85 Years | Shanghai Chest Hospital | |
| Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | NCT01942629 | Lung Adenocarci... Breast Adenocar... Pancreatic Duct... | their will be n... | 18 Years - 75 Years | Rambam Health Care Campus | |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | NCT01828112 | Non-Small Cell ... | Ceritinib pemetrexed docetaxel | 18 Years - | Novartis | |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | NCT04460729 | Non-small Cell ... | Capmatinib | 18 Years - | Novartis | |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
